Plain-English translation of NCT06606821 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether , a once-weekly injection, can help reduce fatty deposits that build up inside your heart arteries. The study focuses on people who are overweight or obese and have been diagnosed with coronary artery disease (narrowing of the heart arteries). Researchers believe this medication may help slow or reverse the buildup of plaque in your arteries by reducing inflammation and fat accumulation.
People with heart artery disease face ongoing risk of heart attacks and other serious complications. Early laboratory studies suggest this medication may have protective effects on blood vessels, but researchers need to confirm whether it actually works this way in real patients and can reduce the dangerous fatty core inside existing plaques.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either the medication or a placebo (a dummy injection) given as a shot under the skin once per week for 52 weeks. During the study, you'll have heart imaging tests to measure changes in your artery plaques, along with regular clinic visits to monitor your health and check for any side effects. The study will help researchers understand whether this treatment can actually change the composition of fatty buildup in your heart arteries.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Denmark